Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer.

Inamura K, Takazawa Y, Inoue Y, Yokouchi Y, Kobayashi M, Saiura A, Shibutani T, Ishikawa Y.

J Clin Med. 2018 Jul 10;7(7). pii: E172. doi: 10.3390/jcm7070172.

2.

Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes.

Inamura K, Yokouchi Y, Kobayashi M, Ninomiya H, Sakakibara R, Subat S, Nagano H, Nomura K, Okumura S, Shibutani T, Ishikawa Y.

Oncotarget. 2017 Apr 25;8(17):28725-28735. doi: 10.18632/oncotarget.15647.

3.

Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis.

Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, Nagano H, Nomura K, Okumura S, Shibutani T, Ishikawa Y.

Lung Cancer. 2017 Jan;103:44-51. doi: 10.1016/j.lungcan.2016.11.013. Epub 2016 Nov 17.

PMID:
28024695
4.

Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.

Hasegawa J, Sue M, Yamato M, Ichikawa J, Ishida S, Shibutani T, Kitamura M, Wada T, Agatsuma T.

Cancer Biol Ther. 2016 Nov;17(11):1158-1167. Epub 2016 Sep 21.

5.

WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis.

Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, Nagano H, Nomura K, Okumura S, Shibutani T, Ishikawa Y.

Lung Cancer. 2016 Dec 10;243:21-28. doi: 10.1016/j.lungcan.2016.09.016. Epub 2016 Oct 1.

PMID:
27721121

Supplemental Content

Loading ...
Support Center